^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MAGE A3 TCR

i
Other names: MAGE A3 TCR, anti-MAGE A3 HLA-A-01-restricted TCR, anti-MAGE-A3-DP4-TCR, anti-MAGE-A3-TCR
Associations
Company:
Gilead, National Cancer Institute
Drug class:
TCR modulator, MAGE-A3 modulator
Related drugs:
Associations
over3years
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov)
P1/2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2021 | Trial primary completion date: Dec 2023 --> Mar 2021
Clinical • Trial completion • Trial completion date • Trial primary completion date
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • MAGEA3 (MAGE Family Member A3)
|
fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous